Join Growin Stock Community!

Pharmacyte biotech, inc.PMCB.US Overview

US StockHealthcare
(No presentation for PMCB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

PMCB AI Insights

PMCB Overall Performance

PMCB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PMCB Recent Performance

1.36%

Pharmacyte biotech, inc.

0.05%

Avg of Sector

-0.31%

S&P500

PMCB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

PMCB Key Information

PMCB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

PMCB Profile

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Price of PMCB

PMCB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PMCB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.04
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.21
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.04
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.21
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is PMCB's latest earnings report released?

    The most recent financial report for Pharmacyte biotech, inc. (PMCB) covers the period of 2026Q2 and was published on 2025/10/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PMCB's short-term business performance and financial health. For the latest updates on PMCB's earnings releases, visit this page regularly.

  • How much cash does PMCB have?

    At the end of the period, Pharmacyte biotech, inc. (PMCB) held Total Cash and Cash Equivalents of 15.41M, accounting for 0.28 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PMCB's EPS continuing to grow?

    According to the past four quarterly reports, Pharmacyte biotech, inc. (PMCB)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.24. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PMCB?

    Pharmacyte biotech, inc. (PMCB)'s Free Cash Flow (FCF) for the period is -979.52K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 7.13% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of PMCB?

    The latest valuation data shows Pharmacyte biotech, inc. (PMCB) has a Price-To-Earnings (PE) ratio of -0.77 and a Price/Earnings-To-Growth (PEG) ratio of -0.23. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.